EasyCookieInfo

Genomica e medicina personalizzata. Takis, l’eccellenza italiana di biotecnologie, sfida l’Europa

L’azienda del Tecnopolo di Castel Romano a Roma è tra i 7 finalisti della European Health Catapult. La finale si disputerà il 2 e 3 dicembre a Parigi

ROMA - Takis con i suoi progetti avanzati ha presentato un vaccino terapeutico personalizzato contro il cancro alla European Health Catapult guadagnandosi il posto in finale.  Un risultato raggiunto grazie alla realizzazione di un vaccino terapeutico personalizzato contro il cancro. Si tratta, quindi di una nuova sfida che punta alla medicina personalizzata, della genomica e delle terapie cellulari che molti intravedono come un percorso necessario sul quale investire. 


Il genoma di ciascun tumore, infatti, presenta mutazioni che differiscono da paziente a paziente e generano proteine anomale chiamate neoantigeni, assenti nelle cellule sane. Il vaccino progettato da Takis istruisce le cellule del sistema immunitario a riconoscere i neoantigeni tumorali e ad annientare solo le cellule che li esprimono. Ma poiché ogni tumore è diverso, ciascun paziente ha bisogno di una terapia su misura: il punto di partenza è il sequenziamento del genoma tumorale, che aiuta i ricercatori a costruire un vaccino ad hoc. 

Si tratta di un progetto innovativo, che i ricercatori di Takis stanno portando avanti con competenza ed entusiasmo. E che alla European Health Catapult, alla quale hanno partecipato 42 start up in Europa, ha già catturato l’interesse degli investitori, confermando ancora una volta l’eccellenza della ricerca italiana in campo oncologico. 

“Siamo orgogliosi di questo risultato– ha dichiarato Luigi Aurisicchio, CEO di Takis –. In questi anni abbiamo intrapreso molti  progetti e ci siamo dedicati alla messa a punto di terapie sempre più mirate ed efficaci contro il cancro. Il merito è, anche e soprattutto, dei nostri ricercatori, che mettono la passione in quello che facciamo giorno dopo giorno per aiutare i pazienti in oncologia”. 

Dello stesso avviso anche Fabio Palombo, responsabile del programma di ricerca: “Grazie alla crescente conoscenza in Immuno-Oncologia, al Next Generation Sequencing  e a tecnologie sempre più efficaci, è possibile oggi pensare a approcci di medicina personalizzata inconcepibili fino a pochissimi anni fa. E noi Italiani con le nostre idee e la nostra fantasia, possiamo dare un grandissimo contributo a questo campo in continua evoluzione”.

Con la sua esperienza nelle terapie innovative contro il cancro, Takis è l’unica azienda italiana ad aver raggiunto questo traguardo, dimostrando di essere tra le 7 migliori imprese biotech in Europa. Merito di un’intensa attività di ricerca, che ha saputo intercettare i temi più all’avanguardia nella lotta ai tumori di questi ultimi anni. Come ad esempio l’immunoterapia, che sfrutta il sistema immunitario per combattere il cancro, dando vita a terapie potenzialmente più efficaci di quelle tradizionali, e soprattutto più mirate. La produzione scientifica di Takis, infatti, appare sempre più orientata al futuro, che è quello della medicina di precisione e su misura del paziente. Una possibilità che oggi, grazie alla conoscenza approfondita del genoma umano, si sta facendo sempre più concreta. 

 

 

LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

Tumor Reduction Demonstrated In Vivo Using Two Linear DNA Vaccines in Animal Models

STONY BROOK, N.Y., September 19, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its majority-owned subsidiary focused on next-generation biotherapeutics, and its collaborators Takis/Evvivax have completed pre-clinical animal studies of two vaccine candidates produced with linear DNA. Tests of both vaccines in mouse models demonstrated their ability to eliminate tumors in vivo, and to potentially prevent initial occurrence.

Evvivax S.R.L. designed a synthetic gene sequence to produce immunity in companion animals, directed against the protein telomerase (TERT), which is overexpressed in 85% of all mammalian cancers, whereas Takis S.R.L. designed a neoantigen-based cancer vaccine (TK), as a proof-of-concept of personalized immunology. For the studies, the TERT and TK based vaccines were produced in linear DNA form by LineaRx. Here is a summary of the recently completed studies performed in vivo:

Previous results from Phase 1 of the collaboration’s Joint Development Agreement (JDA) confirmed immunogenicity in mice that were vaccinated with linear DNA against the human protein telomerase. The results reported herein are from the Phase 2 of the JDA using mice implanted with murine colon cancer.
In the prophylactic use of the telomerase vaccine, wherein vaccination is done before addition of tumor cell lines to the mice, transplanted tumors were cleared within 10 days.
In the therapeutic application using either TERT or TK linear DNA vaccine application, cancer cells were introduced and allowed to grow before administration of the vaccine. The successful reduction of total tumor mass was accomplished in conjunction with antibodies that targeted PD-1 and CTLA4. These antibodies, known as Checkpoint Inhibitors, are commonly used in oncology strategies that rely upon immunotherapy. In this setting the tumor cells were reduced significantly within 30 days.
The strategy of the Takis TK neoantigen vaccine uses unique multiple-target antigenic epitopes that have been identified from the tumor of a human patient. The linear DNA can utilize the genes for several of the most effective universal antigens such as TERT, or neoantigens that are more personalized to the patient.

“We know that immune system has a key role in fighting cancer” said Dr. Luigi Aurisicchio, CEO of Takis/Evvivax. “Thanks to a deep knowledge of cancer immunobiology and cutting-edge vaccination technologies we have now the tools to provide new therapies to our pet friends and human patients.”

For more information please see the Press Release from Applied DNA Sciences adnas

 

Expertscape: the research on cancer vaccines of Takis is an excellence in Italy

The American platform Expertscape has included our CEO and CSO, Dr. Luigi Aurisicchio, in the list of top experts on cancer vaccines in Italy. He ranks  second in the list, and he becomes first considering only biotech companies and Rome and central Italy. The capital city, in particular, ranks third in Italy, confirming itself as a geographical center of excellence in biotech research against cancer.

 

Expertscape, designed by researchers from the University of North Carolina, is an independent rating platform, which bases its ranking on the number of publications by specialists in the various fields of medicine. Especially, studies published in the last decade are taken into consideration as well as the quality of the magazine, the position of the author within the article and the type of scientific work.

Aurisicchio has published 23 articles over the past 10 years dedicated to therapeutic vaccines against cancer. Its scientific production ranges from human to veterinary medicine and in recent years appears increasingly projected towards the future, which is that of precision medicine and personalized therapies.

"Takis represents excellence in the panorama of Italian biotechnology companies - declared Aurisicchio - in recent years we have undertaken many projects and we have dedicated ourselves to developing increasingly targeted and effective therapies against cancer. The merit is also and of our researchers, who put passion into what we do day after day to help patients in oncology ".

Congratulations to Luigi Aurisicchio for this prestigious award.

Link to Expertscape: http://www.expertscape.com/ex/cancer+vaccines/c/it

18 July 2019 – Takis presents its innovation at “Health Technology and new algorithms for Artificial Intelligence”, Tecnopolo Tiburtino, Rome

Luigi Aurisicchio, CEO/CSO at Takis, has been invited to the event organized by Tecnopolo S.p.A and dedicated to Health Technology and Artificial Intelligence.

The meeting brings togheter companies and academic institutions involved in the study and experimentation of concrete technological solutions in medical field.

Dr. Aurisicchio will deliver a speech about Takis research in precision medicine, as we are developing a personalized cancer vaccine against tumor specific neoantigens (TK-NEO). This is a patient-tailored therapy with the potential to target metastatic and solid tumors, which we already validated in preclinical models.

For Registration:
https://health-technology-intelligenza-artificiale.eventbrite.it
Agenda allegata

Technological innovation has a great impact on health and medicine. This is where we make our contribution by implementing innovative individualized therapies based on the immune system against cancer and rare diseases.

 

4 July 2019 – Takis takes part in the event “Lazio2030: insieme per innovare”

Our CEO/CSO Luigi Aurisicchio has been invited to the event “Lazio2030: insieme per innovare”, because Takis is among the companies that have successfully used regional support to invest in research and innovation.

Since we have decided to invest and create innovation and employment in Lazio region, we have managed to keep the excellent reputation of Italian research by bringing new therapeutic solutions for cancer patients into pre-clinical and clinical stages.

To learn more about Takis’ Rever3mAb, MenHub, High Throughput mAbsclick here ...

To learn more about GENEVAX, led by Evvivax Spin off, click here ...

We are proud to have become part of this community and never going to stop believing in the value of scientific research.

 

4 June 2019 - Takis semifinalist at the European Health Catapult

Takis qualified as a semifinalist at the European Health Catapult organized by EIT Health with the support of the Health Axis Europe. This makes  us among the 14 best biotech companies in Europe!

EIT Health is a network of the best-in-class health innovators backed by the EU, aimed at ensuring a longer and healthier life for European citizens.

European Health Catapult is a training and competition programme that awards the best business concepts from medtech, biotech and digital health across Europe.

Dr Fabio Palombo, Head of Personalized Cancer Vaccine program, will attend the semi-finals in Delft from 24-26 September 2019, where we will participate in Training and Selection Days. This is a great opportunity for us to get high quality training in business plan modeling, deal negotiation and pitch as well as to extend our network and approach top level investors.

We are really looking forward to this amazing experience. We are ready to do our best to enhance Italian research in Europe.  

Read about: https://www.europeanhealthcatapult.eu/about/